申请人:Knopp Biosciences LLC
公开号:US20170114022A1
公开(公告)日:2017-04-27
Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.